JPMorgan analyst Cory Kasimov lowered his price target for Clovis Oncology to $71 after "reigning in" his ovarian expectations but keeps an Overweight rating on the shares. With the European Society of Medical Oncology meeting coming up in October, Kasimov is previewing the first look at data from Clovis's Triton-2 study in prostate cancer. The analyst is "quite confident" that the company's PARP inhibitor rucaparib should produce response rates that are well above chemotherapy and anti-androgens, at least in third line BRCA positive patients. He views the Triton-2 update as an important event for Clovis and believes "promising results could represent a step towards restoring more favorable sentiment." A response rate of at least 30% is the lower bar for share appreciation, Kasimov tells investors in a research note. He keeps an Overweight rating on Clovis.